- Proteins and Peptides
- Lysates and Cell Lines
Novus Biologicals announced today a new CHD7 antibody (catalog number NBP1-77393) for use in research on transcription regulation and CHARGE syndrome. This CHD7 antibody was made using SDIX Genomic Antibody TechnologyTM.
CHD7 is an ATP-dependent chromatin remodeler that interacts closely with SOX2 to regulate certain human disease genes. Mutations in CHD7 have been associated with both CHARGE and Kallmann congenital malformation syndromes. These syndromes are characterized by a wide range of symptoms, and are thought to affect neurogenerative anomalies and maturation events through SOX2 interaction.
Novus' new CHD7 Antibody (NBP1-77393) has been thoroughly validated for use in Western blot and immunofluorescent staining on human and mouse samples. This antibody will serve as an important tool for further research on CHD7 function in CHARGE and Kallmann syndromes.
SDIX Genomic Antibody Technology uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to a targeted region of protein in its naturally folded form. The ability of any antibody to recognize a proteins naturally folded state has the potential to expand an antibodys utility to high-value applications like sandwich immunoassay, ChIP and flow cytometry. Learn more about SDIX Genomic Antibodies by reading the SDIX Genomic Antibody FAQ or by downloading the SDIX Genomic Antibody White Paper.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
About SDIX (www.sdix.com)
SDIX is a biotechnology company with a core expertise at creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions Company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.
In the life science market, SDIXs™ technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost effective results.
This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like anticipate, could, enable, estimate, intend, expect, believe, potential, will, should, project, plan and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.